New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
07:32 EDTREGNRegeneron, Bayer announce positive Phase 3 Eylea trial results
Regeneron and Bayer HealthCare announced that in the Phase 3 VISTA-DME trial of EYLEA Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams dosed monthly and EYLEA 2 mg dosed every two months showed a sustained improvement from baseline in best corrected visual acuity at week 100, compared to laser photocoagulation. After two years, patients receiving EYLEA 2Q4 had a mean change from baseline in BCVA of 11.5 letters. Patients receiving EYLEA 2Q8 had a mean change from baseline in BCVA of 11.1 letters. Patients in the laser photocoagulation treatment group had a mean change from baseline in BCVA of 0.9 letters. In this trial, EYLEA was generally well tolerated with a similar overall incidence of adverse events, ocular serious AEs, and non-ocular serious AEs across the EYLEA treatment groups and the laser control group. Bayer HealthCare and Regeneron are collaborating on the global development of EYLEA.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
11:03 EDTREGNRegeneron confirms FDA approval of EYLEA
Subscribe for More Information
10:35 EDTREGNFDA approves expanded indication for Eylea
Subscribe for More Information
March 23, 2015
07:17 EDTREGNAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
10:00 EDTREGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:05 EDTREGNRegeneron initiated with a Buy at Chardan
Subscribe for More Information
March 16, 2015
08:23 EDTREGNPCSK9 data continues to impress, says Leerink
Subscribe for More Information
07:16 EDTREGNRegeneron Sanofi dupilumab drug can generate $6B+ in revenue, says Bernstein
Bernstein believes that dupilumab, a drug made by Regeneron and Sanofi, has shown strong efficacy in patients with severe atopic dermatitis. The firm notes that the drug is currently in pivotal trials involving patients with severe levels of other common diseases. The firm thinks the drug can generate $1.5B of revenue by 2018 and $3.8B by 2020. Bernstein keeps a $500 price target and Outperform rating on Regeneron.
06:40 EDTREGNPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
March 15, 2015
13:04 EDTREGNSanofi, Regeneron announce publication of results of ODYSSEY long term trial
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) today announced that 18-month results of a Phase 3 trial of Praluent, alirocumab, an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol by an additional 62% at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks."These results demonstrated the durable efficacy for Praluent when added to maximally-tolerated statin therapy and further reinforce its generally consistent safety profile," said Jennifer Robinson, M.D., M.P.H., Director of the Prevention Intervention Center, Professor, Departments of Epidemiology & Medicine, College of Public Health at the University of Iowa. "Additionally, the post hoc analysis of major cardiovascular events represents an important finding for Praluent -- we look forward to results from the ongoing ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential of Praluent to reduce cardiovascular events."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use